A Novel Catalytically Inactive Construct of Botulinum Neurotoxin A (BoNT/A) Directly Inhibits Visceral Sensory Signalling

A Novel Catalytically Inactive Construct of Botulinum Neurotoxin A (BoNT/A) Directly Inhibits Visceral Sensory Signalling

Botulinum neurotoxin A (BoNT/A) is a potent neurotoxin that silences cholinergic neurotransmission through the cleavage of the synaptic protein SNAP-25. Previous studies have shown that, in addition to its paralytic effects, BoNT/A can inhibit sensory nerve activity. The aim of this study was to ide...

Full description

Bibliographic Details
Main Authors:	Hodan Ibrahim, Kevin Retailleau, Fraser Hornby, Jacquie Maignel, Matthew Beard, Donna Marie Daly
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	Toxins
Subjects:	botulinum toxin sensory bladder nerve mechanosensitivity
Online Access:	https://www.mdpi.com/2072-6651/16/1/30

Similar Items

BoNT/A in the Urinary Bladder—More to the Story than Silencing of Cholinergic Nerves
by: Hodan Ibrahim, et al.
Published: (2022-01-01)

Navigating the Complexities Involving the Identification of Botulinum Neurotoxins (BoNTs) and the Taxonomy of BoNT-Producing Clostridia
by: Theresa J. Smith, et al.
Published: (2023-09-01)

Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism
by: Robert P. Webb, et al.
Published: (2017-09-01)

Botulinum Neurotoxin BoNT-A in the Management of Hypertrophic Scars and Keloids: A Comprehensive Review
by: Ramadan S. Hussein
Published: (2024-03-01)

BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study
by: Jacquie Maignel, et al.
Published: (2022-01-01)

The use of botulinum toxin (BoNT) in urology - review
by: Jakub Szwed, et al.
Published: (2022-08-01)

Botulinum toxin (BoNT) in the correction of mimic wrinkles - the most common complications
by: Monika Szwed, et al.
Published: (2022-08-01)

Exploring the genetic background of the botulism neurotoxin BoNT/B2 in Spain
by: Sylvia Valdezate, et al.
Published: (2023-10-01)

Preclinical Evidence for the Role of Botulinum Neurotoxin A (BoNT/A) in the Treatment of Peripheral Nerve Injury
by: Michael Adler, et al.
Published: (2022-04-01)

Botulinum Neurotoxins (BoNTs) and Their Biological, Pharmacological, and Toxicological Issues: A Scoping Review
by: Massimo Corsalini, et al.
Published: (2021-09-01)

The Light Chain Domain and Especially the C-Terminus of Receptor-Binding Domain of the Botulinum Neurotoxin (BoNT) Are the Hotspots for Amino Acid Variability and Toxin Type Diversity
by: Renmao Tian, et al.
Published: (2022-10-01)

The Isolated Mouse Jejunal Afferent Nerve Assay as a Tool to Assess the Effect of Botulinum Neurotoxins in Visceral Nociception
by: Kevin Retailleau, et al.
Published: (2022-03-01)

Expression, Purification and evaluation of the Immunogenicity of RecombinantC-terminus of the Receptor-Binding Domain of Neurotoxin Botulinum Protein Type B (BoNT/B-HcC)
by: Hossein Samiei Abianeh, et al.
Published: (2023-08-01)

New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency
by: David Burgin, et al.
Published: (2021-11-01)

Botulinum Neurotoxins (BoNTs)—Antibody and Vaccine
by: Jianlong Lou, et al.
Published: (2018-11-01)

Comparison of botulinum toxin (BoNT) injection and lateral internal sphincterotomy (redo-LIS) for recurrent anal fissure treatment
by: Ahmet Alyanak, et al.
Published: (2022-09-01)

The Effects of Intradetrusor BoNT-A Injections on Vesicoureteral Reflux in Children With Myelodysplasia
by: Tuncay Toprak, et al.
Published: (2019-12-01)

A novel RRGW derived peptide is a promising inhibitor of BoNT/A
by: Wantong Ma, et al.
Published: (2023-12-01)

Reasons and Determinants of BoNT-A Treatment Discontinuation in Patients Living with Spasticity: A 10-Year Retrospective Analysis
by: Nicoletta Cinone, et al.
Published: (2022-09-01)

Molecular Diversity of BoNT-Producing Clostridia—A Still-Emerging and Challenging Problem
by: Tomasz Grenda, et al.
Published: (2023-03-01)

Outbreaks of iatrogenic botulism in Europe: Combating off-label medical use of Botulinum Neurotoxin (BoNT) in bariatric procedures
by: Nityanand Jain, et al.
Published: (2023-06-01)

A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice
by: Yongfeng Fan, et al.
Published: (2023-04-01)

BoNT-A for Post-Stroke Spasticity: Guidance on Unmet Clinical Needs from a Delphi Panel Approach
by: Alessio Baricich, et al.
Published: (2021-03-01)

Why Are Botulinum Neurotoxin-Producing Bacteria So Diverse and Botulinum Neurotoxins So Toxic?
by: Bernard Poulain, et al.
Published: (2019-01-01)

Subcutaneous BoNT/A Injection for Intractable Pain and Disability in Complex Regional Pain Syndrome: A Case Report
by: Yan Tereshko, et al.
Published: (2022-06-01)

Adjunctive treatment and BoNT-A for post-stroke spasticity: Are we really focusing on the patient-centered goals?
by: Alessio Baricich, et al.
Published: (2023-03-01)

Are paraspinous intramuscular injections of botulinum toxin a (BoNT-A) efficient in the treatment of chronic low-back pain? A randomised, double-blinded crossover trial
by: Mélanie Cogné, et al.
Published: (2017-11-01)

High Precision Use of Botulinum Toxin Type A (BONT-A) in Aesthetics Based on Muscle Atrophy, Is Muscular Architecture Reprogramming a Possibility? A Systematic Review of Literature on Muscle Atrophy after BoNT-A Injections
by: Alexander D. Nassif, et al.
Published: (2022-01-01)

Effect of BoNT/A in the Surface Electromyographic Characteristics of the Pelvic Floor Muscles for the Treatment of Chronic Pelvic Pain
by: Monica Albaladejo-Belmonte, et al.
Published: (2021-07-01)

Human-Relevant Sensitivity of iPSC-Derived Human Motor Neurons to BoNT/A1 and B1
by: Maren Schenke, et al.
Published: (2021-08-01)

Editorial: New insights on botulism, botulinum neurotoxins, and botulinum toxin-producing clostridia
by: Fabrizio Anniballi, et al.
Published: (2022-07-01)

Alpha-Latrotoxin Rescues SNAP-25 from BoNT/A-Mediated Proteolysis in Embryonic Stem Cell-Derived Neurons
by: Patrick McNutt, et al.
Published: (2011-05-01)

Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A).
by: Birgitte P S Jacky, et al.
Published: (2013-01-01)

Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS.
by: Suzanne R Kalb, et al.
Published: (2010-08-01)

The Efficacy of Transvaginal Ultrasound-Guided BoNT-A External Sphincter Injection in Female Patients with Underactive Bladder
by: Cheng-Yen Tsai, et al.
Published: (2023-03-01)

Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature
by: Michael W. Peck, et al.
Published: (2017-01-01)

Zebrafish Sensitivity to Botulinum Neurotoxins
by: Kamalakar Chatla, et al.
Published: (2016-05-01)

Use of Botulinum Neurotoxin in Ophthalmology
by: Emel Başar, et al.
Published: (2016-12-01)

Therapy of Sialorrhea with Botulinum Neurotoxin
by: Wolfgang H. Jost, et al.
Published: (2019-09-01)

Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay
by: Nicholas G. James, et al.
Published: (2021-04-01)